Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver
This trial is active, not recruiting.
|Conditions||hepatitis b, liver transplantation|
|Treatment||adefovir dipivoxil and hepatitis b vaccination|
|Start date||March 2006|
|End date||July 2012|
|Trial size||16 participants|
|Trial identifier||NCT01146808, AAAB8413, IN-US-103-0158|
The primary purpose of this study is to evaluate the efficacy of adefovir (ADV) in preventing de novo Hepatitis B in patients who receive Hepatitis B core antibody (HBcAb) positive grafts but who are not Hepatitis B Surface antigen (HBsAg) positive prior to transplant (Hepatitis B naive patients). The second objective is to evaluate the efficacy of accelerated vaccination with Hepatitis B in inducing innate immunity, thereby obviating the need for life-long antiviral therapy.
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Development of de novo hepatitis B infection after transplant with a core antibody positive liver
time frame: Standard of care visits post-transplant for 2 years
Proportion of patients with a sustained hepatitis B surface antibody titer > 500 IU/mL prior to and after vaccination
time frame: 12-18 months post transplant
Proportion of patients who develop de novo hepatitis B infection post ADV withdrawal, which will be assessed at 6 months post withdrawal
time frame: Six months after hepatitis B vaccination (2 years post transplant)
Male or female participants at least 18 years old.
- Recipients who do not have evidence of hepatitis B surface antigen, regardless of HBcAb and HBsAb status, who:
- received liver transplantation with hepatitis B core antibody positive (and HBsAg negative) grafts,
- received adefovir treatment post transplantation, and
- who have not reached the 18 month post transplantation time period.
- Recipients with hepatitis B surface antigen positivity prior to liver transplant.
- Grafts from hepatitis B surface antigen positive patients.
- Previous intolerance to ADV therapy
- Recipients with pre-transplant creatinine > 1.6 mg/dL
- Patients younger than 21 years of age
- Patients who are pregnant or breastfeeding
|Official title||Prevention of de Novo Hepatitis B Infection With Adefovir Dipivoxil (ADV) and Hepatitis B Vaccination in HBsAg Seronegative Recipients of Liver Grafts From Hepatitis B Core Antibody Positive (HBcAb+) Donors|
|Principal investigator||Robert S Brown, Jr, MD, MPH|
|Description||The investigators will conduct a prospective, open-label study of Hepatitis B naive patients who received HBcAb + livers and adefovir prophylaxis post-transplant. At one year to 18 months following transplantation, all study patients will then be vaccinated with standard Hepatitis B vaccine at double dose on a monthly basis for three months, at which point they will be tested for Hepatitis B surface antibody (HBsAb). Any study patients that have developed a sufficient antibody response (HBsAb >500 IU) will be given the option to discontinue anti-viral treatment in a monitored setting.|
Call for more information